Publicacións nas que colabora con ANA DE LORENZO PINTO (2)

2018

  1. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

    Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241

2017

  1. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project

    International Journal of Clinical Practice, Vol. 71, Núm. 8